Resultado de búsqueda
23 de jun. de 2023 · Curious about artificial implantable organs? We're excited to hear from Dr. Shuvo Roy, who is helping shape the future of this kidney innovation through @KidneyProject @UCSF and @VUMCKidney! Join us for the latest at this year's Global Summit! Register: http://bit.ly/AAKPGlobal . 23 Jun 2023 22:00:28
2 de mar. de 2023 · Atypical hemolytic uremic syndrome (aHUS) is a devastating form of thrombotic microangiopathy (TMA) predominantly involving the kidney. 1 Untreated, it leads to end-stage renal disease in up to 2 out of 3 affected patients, shortly after onset or following relapses. 2-4 The unraveling of the pathogenic mechanisms underlying aHUS, namely an overactivation of the complement alternative pathway ...
Eculizumab has been used pre-emptively for renal transplant in aHUS and prophylactically after renal transplantation (43,54,69). The best results in terms of normalizing renal function were obtained when eculizumab was given as soon as possible after onset of aHUS . Eculizumab also successfully treated skin necrosis in aHUS .
Background: Atypical hemolytic uremic syndrome (aHUS) is a rare disorder with a high probability of recurrence after a kidney transplant and can adversely affect the graft outcome. Our objective was to assess the transplant outcome of patients with aHUS who had undergone a kidney transplant.
Hace 4 días · The data of women who were admitted with postpartum AKI from January 2021 to October 2023 was retrospectively collected and analyzed. We used the following criteria to diagnose postpartum atypical HUS (Serum creatinine ≥1.9 mg/dL, Lactate dehydrogenase (LDH) ≥1832 U/L, or serum creatinine ≥1.9 mg/dL in combination with LDH ≥ ...
13 de ago. de 2020 · Abstract. Background. Kidney transplantation (KTx) is a strong trigger for the development of either recurrent or de novo atypical haemolytic uraemic syndrome (aHUS). According to previous studies, eculizumab (ECU) is effective for prophylaxis and for treatment of recurrence. Methods.
Atypical hemolytic and uremic syndrome (aHUS) is a severe disease strongly associated with genetic abnormalities in the complement alternative pathway. In renal posttransplantation, few data are available on recurrence risk and graft outcome according to genetic background in aHUS patients.
